01:35 AM EST, 11/09/2026 (MT Newswires) -- Argenx (ARGX.BR) agreed to acquire US-based synthetic macrocyclic peptides developer Unnatural Products in a deal valued at up to $1.15 billion, according to a Monday release. Under the transaction, the immunology company, which currently owns a minority stake in Unnatural Products, will acquire the target company for an upfront payment of $550 million in cash and up to $595 million in payments tied to certain milestones. Subject to customary closing conditions, the acquisition is expected to close by the end of 2026. Following closing, Unnatural Products will continue operating from its Santa Cruz, California, site as part of Argenx's global research organization.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.